Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coya Therapeutics (COYA) Income from Continuing Operations (2022 - 2025)

Coya Therapeutics (COYA) has disclosed Income from Continuing Operations for 4 consecutive years, with 12067503.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 21.98% to 12067503.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 3767128.0 through Dec 2025, down 50.64% year-over-year, with the annual reading at 21203089.0 for FY2025, 42.49% down from the prior year.
  • Income from Continuing Operations hit 12067503.0 in Q4 2025 for Coya Therapeutics, up from 2432897.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 12067503.0 in Q4 2025 to a low of 7306757.0 in Q1 2025.
  • Historically, Income from Continuing Operations has averaged 1498944.25 across 4 years, with a median of 2895888.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: surged 445.03% in 2024 and later tumbled 110.78% in 2025.
  • Year by year, Income from Continuing Operations stood at 2003518.0 in 2022, then surged by 190.6% to 1815155.0 in 2023, then soared by 445.03% to 9893190.0 in 2024, then grew by 21.98% to 12067503.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for COYA at 12067503.0 in Q4 2025, 2432897.0 in Q3 2025, and 6094977.0 in Q2 2025.